Podcasts

We traveled to Washington D.C. for a State of the Science Summit on Breast Cancer, which focused on additional recent advances in the NSCLC and small cell lung cancer paradigms, touching on TKIs, immunotherapy, and other investigational agents.

We traveled to Pittsburgh, Pennsylvania for a State of the Science Summit on Breast Cancer, which focused on novel approaches in metastatic triple-negative breast cancer and treatment strategies for patients with brain metastases.

We traveled to San Diego, California, for the 2018 ASH Annual Meeting, where we spoke with several experts across hematologic malignancies, including mantle cell lymphoma, chronic lymphocytic leukemia, and multiple myeloma.

We headed to San Antonio, Texas, for the San Antonio Breast Cancer Symposium, where we spoke to several principal investigators who detailed new applications of novel therapies, surgical intervention strategies, and lifestyle modifications.

We headed to Stanford, California, for a State of the Science Summit on Ovarian Cancer and Soft Tissue Sarcoma, which focused on recent advances made in the treatment landscapes.

We headed to Chicago, Illinois, for a State of the Science Summit on Advanced Non–Small Cell Lung Cancer, which focused on recent updates in the field, particularly data from the 2018 World Conference on Lung Cancer.

We headed to Charlotte, North Carolina, for a State of the Science Summit on Genitourinary Cancers, which focused on the evolving paradigms of prostate cancer and renal cell carcinoma.

We headed to Clayton, Missouri for a State of the Science Summit on Hematologic Malignancies, which focused on novel agents in chronic lymphocytic leukemia, advances in acute myeloid leukemia, progress in myeloproliferative neoplasms, and more.

We headed to Newport Beach, California, for a State of the Science Summit on Gastrointestinal Cancers, which focused on the evolving paradigms of colorectal cancer, pancreatic cancer, neuroendocrine tumors, gastric cancer, and hepatocellular carcinoma.

The 2018 ESMO Congress brought us all the way to Munich, Germany. At this annual congress, data across various tumor types were presented, including genitourinary malignancies, breast cancer, head and neck squamous cell carcinoma, melanoma, gastrointestinal malignancies, and lung cancer.

We traveled to Cleveland, Ohio for a State of the Science Summit on Hematologic Malignancies. The meeting covered the evolving paradigm of chronic lymphocytic leukemia, updates in mantle cell lymphoma, treatment options for patients with newly diagnosed and relapsed/refractory multiple myeloma, unmet needs in myeloproliferative neoplasms, interesting genomic research in acute myeloid leukemia, and the challenges with treating patients with myelodysplastic syndrome.

We returned to San Francisco, California for a State of the Science Summit on Breast Cancer. The meeting covered the use of CDK4/6 inhibitors in metastatic hormone receptor-positive breast cancer, adjuvant and neoadjuvant HER2-targeted therapy in early-stage HER2-positive disease, immunotherapy in triple-negative disease, and more.

We visited San Francisco, California for a State of the Science Summit on Hematologic Malignancies. The meeting covered novel agents and combinations in lymphoma, updates in acute and chronic leukemias, and modalities in the management of multiple myeloma.

We visited Chicago, Illinois for a State of the Science Summit on Renal Cell Carcinoma and Bladder Cancer. The meeting covered the genomics of bladder cancer, novel approaches to non-muscle invasive bladder cancer, side effect management from immunotherapy, as well as the integration of immunotherapy, chemotherapy, and targeted therapy in genitourinary cancers.

We traveled to Seattle, Washington for another State of the Science Summit on Hematologic Malignancies with faculty of Seattle Cancer Care Alliance and Fred Hutchinson Cancer Research Center. The meeting covered the latest updates in Hodgkin lymphoma, mantle cell lymphoma, multiple myeloma, and more.

We visited Dearborn, Michigan for a State of the Science Summit on Hematologic Malignancies with faculty of Karmanos Cancer Institute.

We headed to Tampa, Florida for a State of the Science Summit on Hematologic Malignancies. The meeting covered updates in follicular lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, multiple myeloma, acute lymphoblastic leukemia, chronic myeloid leukemia, acute myeloid leukemia, myeloproliferative neoplasms, and CAR T-cell therapy.

We traveled to Hanover, Maryland for a State of the Science SummitTM on Advanced Non–Small Cell Lung Cancer. The meeting covered the use of immunotherapy in metastatic and early-stage disease, management of immune-related toxicities, predictive biomarkers, and emerging therapies in small cell lung cancer.

We traveled to Charlotte, North Carolina for a State of the Science Summit on Ovarian Cancer. The meeting covered genetic testing, frontline therapies, surgical options, treatment for recurrent disease, immunotherapy, and updates in uterine sarcomas.

This Dallas, Texas meeting on gastrointestinal (GI) cancers covered emerging therapies in pancreatic cancer, updates in neuroendocrine tumors, the management of metastatic colorectal cancer, recent data in hepatocellular carcinoma, and the clinical application of precision medicine in GI cancers.

We traveled to Charlottesville, Virginia for a State of the Science Summit on Advanced Non-Small Cell Lung Cancer. The conference spanned early-stage advances, established and emerging treatments for oncogenic-driven disease, chemotherapy, immunotherapy, and the role of radiation

We went out to Denver, Colorado for a State of the Science Summit on Advanced Non–Small Cell Lung Cancer. The conference spanned screening, molecular profiling, early-stage advances, treatment for oncogenic-driven advanced disease, and immunotherapy.

We traveled to Houston, Texas for a State of the Science Summit on Breast Cancer on July 11, 2018. The conference covered radiation therapy, triple-negative breast cancer, BRCA-positive tumors, takeaways from the 2018 ASCO Annual Meeting, and more.

We headed out to Kansas City, Missouri, for a State of the Science Summit on June 30, 2018, which spanned several tumor types and covered the highlights from the 2018 ASCO Annual Meeting.